SureTrader Nadex Advertisement PGUS
Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

Add IDRA Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 3/26/2017 10:13:55 PM - Followers: 160 - Board type: Free - Posts Today: 0

The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.

In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.

IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.

The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
IDRA News: Amended Annual Report (10-k/a) 03/16/2017 04:03:51 PM
IDRA News: Annual Report (10-k) 03/15/2017 05:05:49 PM
IDRA News: Current Report Filing (8-k) 03/13/2017 05:00:25 PM
IDRA News: Idera to Present at the 37th Annual Cowen and Company Health Care Conference 03/02/2017 07:30:00 AM
IDRA News: Idera Pharmaceuticals Presents Update from Ongoing Phase 1 Dose Escalation Clinical Trial of Intratumoral IMO-2125 in Combina... 02/24/2017 11:30:00 AM
#2861   "Could IDRA be sitting on a blockbuster?" Citrati 03/26/17 10:13:55 PM
#2860   Could Idera Pharmaceuticals Inc (NASDAQ:IDRA) Be Sitting On usasingh1 03/25/17 01:11:27 AM
#2859   Here is the 3 year weekly perspective and Citrati 03/23/17 12:27:20 AM
#2858   Feeling good here Stay green my friend ;-) Cbdpotential 03/22/17 11:19:16 PM
#2857   ;-) $IDRA Cbdpotential 03/22/17 10:53:23 PM
#2856   * * $IDRA Video Chart 03-22-17 * * ClayTrader 03/22/17 04:41:48 PM
#2855   Congrats everyone. We will have our ups and Citrati 03/22/17 10:02:19 AM
#2854   JMP Securities initiated at Outperform w/$8 price target. Cre8tivmynd 03/22/17 09:13:03 AM
#2853   Doc7 who upgraded it?? the gipper 03/22/17 09:06:49 AM
#2852   Upgraded to outperform doc7 03/22/17 08:41:39 AM
#2850   Very nice day today. :-D :-D Citrati 03/20/17 03:05:08 PM
#2848   just google it. Pretty simple. Shows the success kld2 03/20/17 05:50:10 AM
#2847   91% fails where did you get this information youssef 03/19/17 11:35:02 PM
#2846   Well I did something I never did before attilathehunt 03/17/17 07:58:02 PM
#2845   Love this post! Go $IDRA Cbdpotential 03/17/17 02:42:38 PM
#2844   :-D Two thumbs up. Citrati 03/16/17 01:44:05 PM
#2843   Why is IDERA different from other biotechs with kld2 03/16/17 07:56:44 AM
#2842   Nice ER!!! homdance 03/15/17 06:14:19 PM
#2841   As long as science continues progressing price movement Citrati 03/06/17 11:16:36 PM
#2840   Been apart of many, many head fakes and Farmmarket1 03/06/17 08:54:20 AM
#2839   I generally don't post when I have no chmcnfunds 03/06/17 07:48:57 AM
#2838   Just need to cool down a little. Get Citrati 03/05/17 11:24:16 PM
#2837   This uptrend is not based around a SA Farmmarket1 03/04/17 11:55:15 AM
#2836   Another smiley face day. :-) Citrati 03/02/17 12:51:57 PM
#2835   Smiley face here, but I sold yesterday. Generally chmcnfunds 03/01/17 08:26:24 AM
#2834   Nice move. Fortunately,I doubled down after ASCO (once kld2 03/01/17 07:06:02 AM
#2833   :-D GREEN Cbdpotential 02/28/17 05:59:36 PM
#2832   Go $IDRA! Great day Cbdpotential 02/28/17 05:59:20 PM
#2831   See what happens when/if we get to 2.06. Citrati 02/28/17 11:39:58 AM
#2830   Where are all the smiley faces? A great Citrati 02/28/17 10:24:41 AM
#2829   Long bullish SA article: chmcnfunds 02/27/17 04:30:03 PM
#2828   From the PR: chmcnfunds 02/24/17 11:48:36 AM
#2827   Idera Pharmaceuticals Presents Update from Ongoing Phase 1 chmcnfunds 02/24/17 11:42:56 AM
#2826   Definitely counter IBB trend. :-) Citrati 02/23/17 06:09:13 PM
#2825   Real strong finish at close with ~50,000 shares chmcnfunds 02/23/17 04:04:45 PM
#2824   I had to add the 200 to my chmcnfunds 02/22/17 08:30:24 AM
#2823   The abstract: chmcnfunds 02/22/17 08:02:30 AM
#2822   As I interpret the ink blot, it entered Citrati 02/21/17 04:17:03 PM
#2821   I imagine we should get a pr tomorrow kld2 02/21/17 11:37:55 AM
#2820   I'm referring to over-bought as evidenced by technical chmcnfunds 02/21/17 10:43:53 AM
#2819   Overbought? I would say it's been oversold for months. kld2 02/21/17 10:02:29 AM
#2818   I agree with you generally except the charts chmcnfunds 02/21/17 09:55:29 AM
#2817   I don't expect much from IDRA abstract. A kld2 02/21/17 06:15:35 AM
#2816   Very much so, 2017-2018 will be a complete Farmmarket1 02/20/17 02:30:38 PM
#2815   Agreed. Excellent addition from you. Citrati 02/20/17 12:57:25 PM
#2814   8:45 into webcast still gets me more excited Farmmarket1 02/20/17 11:30:49 AM
#2813   Check this out if you haven't already. Citrati 02/18/17 10:32:47 PM
#2812   Abstracts: Embargo Policy chmcnfunds 02/17/17 02:00:37 PM
#2811   Solid volume: chmcnfunds 02/17/17 12:17:17 PM
#2810   IDRA, IMO, has the key elements to very kld2 02/17/17 08:33:43 AM